These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 7465847)

  • 1. Therapeutic intraperitoneal 32P: a clinical assessment of the dynamics of distribution.
    Kaplan WD; Zimmerman RE; Bloomer WD; Knapp RC; Adelstein SJ
    Radiology; 1981 Mar; 138(3):683-8. PubMed ID: 7465847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Letter: Loculation as a contraindication to intracavitary 32P-chromic phosphate therapy.
    Vider M; Deland FH; Maruyama Y
    J Nucl Med; 1976 Feb; 17(02):150-1. PubMed ID: 1245879
    [No Abstract]   [Full Text] [Related]  

  • 3. The use of scintigraphic and contrast peritoneography in gynecologic malignancies.
    Yoonessi M; Abdel-Dayem HM; Shalaby OF
    Diagn Gynecol Obstet; 1982; 4(1):75-8. PubMed ID: 7075451
    [No Abstract]   [Full Text] [Related]  

  • 4. Radioactivity in blood and urine following intraperitoneal instillation of chromic phosphate in patients with and without ascites.
    Bakri YN; Given FT
    Am J Obstet Gynecol; 1984 Sep; 150(2):184-8. PubMed ID: 6476040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peritoneoscintigraphy in detection of improper placement of peritoneal catheter into bowel lumen prior to chromic phosphate P-32 therapy. A case report.
    Neutze J; Van Nostrand D; Major W
    Clin Nucl Med; 1985 Nov; 10(11):777-9. PubMed ID: 4075668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: a phase II Hoosier Oncology Group (HOG 97-01) study.
    Fakiris AJ; Moore DH; Reddy SR; Look KY; Yiannoutsos CT; Randall ME; Cardenes HR;
    Gynecol Oncol; 2005 Mar; 96(3):818-23. PubMed ID: 15721431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pleuroperitoneal migration of intraperitoneal phosphorus-32-chromic phosphate therapy for stage I ovarian carcinoma.
    Wilkinson RH
    J Nucl Med; 1996 Apr; 37(4):636-9. PubMed ID: 8691256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution and tissue dose of intraperitoneally administered radioactive chromic phosphate (32P) in New Zealand white rabbits.
    Leichner PK; Rosenshein NB; Leibel SA; Order SE
    Radiology; 1980 Mar; 134(3):729-34. PubMed ID: 7355227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraperitoneal distribution imaging prior to chromic phosphate (P-32) therapy in ovarian cancer patients.
    Tulchinsky M; Eggli DF
    Clin Nucl Med; 1994 Jan; 19(1):43-8. PubMed ID: 8137583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraperitoneal chromic phosphate P 32 suspension therapy of malignant peritoneal cytology in endometrial carcinoma.
    Soper JT; Creasman WT; Clarke-Pearson DL; Sullivan DC; Vergadoro F; Johnston WW
    Am J Obstet Gynecol; 1985 Sep; 153(2):191-6. PubMed ID: 4037013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loculation as a contraindication intracavitary 32P-chromic phosphate therapy.
    Taylor A; Baily NA; Halpern SE; Ashburn WL
    J Nucl Med; 1975 Apr; 16(4):318-9. PubMed ID: 1113189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: the Indiana University experience.
    Fakiris AJ; Henderson M; Lo SS; Look KY; Cardenes HR
    Brachytherapy; 2010; 9(1):61-5. PubMed ID: 20129252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-body distribution of radioactivity after intraperitoneal administration of 32P colloids.
    Boye E; Lindegaard MW; Paus E; Skretting A; Davy M; Jakobsen E
    Br J Radiol; 1984 May; 57(677):395-402. PubMed ID: 6722434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraperitoneal chromic phosphate in ovarian cancer: risks and benefits.
    Potter ME; Partridge EE; Shingleton HM; Soong SJ; Kim RY; Hatch KD; Austin JM
    Gynecol Oncol; 1989 Mar; 32(3):314-8. PubMed ID: 2920951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioisotopes in the treatment of ovarian cancer.
    Rosenshein NB
    Clin Obstet Gynaecol; 1983 Aug; 10(2):279-95. PubMed ID: 6617040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraperitoneal radioactive chromic phosphate (P32) in the treatment of ovarian cancer.
    Powell JL; Kirchner AB
    J Med Assoc Ga; 1984 Jan; 73(1):21-5. PubMed ID: 6707541
    [No Abstract]   [Full Text] [Related]  

  • 17. 32P following negative second-look laparotomy for epithelial ovarian cancer.
    Rogers L; Varia M; Halle J; Freddo J; Qaqish B; O'Keefe T; Fowler W
    Gynecol Oncol; 1993 Aug; 50(2):141-6. PubMed ID: 8375727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphorus-32-chromic phosphate for ovarian cancer: I. Fractionated low-dose intraperitoneal treatments in conjunction with platinum analog chemotherapy.
    Pattillo RA; Collier BD; Abdel-Dayem H; Ozker K; Wilson C; Ruckert AC; Hamilton K
    J Nucl Med; 1995 Jan; 36(1):29-36. PubMed ID: 7799078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peritoneal fluid cytology in endometrial cancer: its significance and the role of chromic phosphate (32P) therapy.
    Heath R; Rosenman J; Varia M; Walton L
    Int J Radiat Oncol Biol Phys; 1988 Oct; 15(4):815-22. PubMed ID: 3182321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose estimation to the infant from breast milk following intraperitoneal administration of chromic phosphate 32P for the treatment of early ovarian cancer.
    Sharma SC; Osborne RP; Jose B; Carlson JA
    Health Phys; 1984 Sep; 47(3):452-4. PubMed ID: 6500947
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.